Covid-19 – lessons learned
Abstract
Modern society has not forgotten yet epidemics that have killed millions in the last millennium, and the COVID 19 pandemic caused by the SARS CoV-2 has emerged. With the onset of the Wuhan epidemic in the Chinese province of Hubei, the initially called a new corona virus due to similarity of 80% to the 2020 SARS virus was renamed to SARS CoV-2. The virus was originally isolated in bronchoalveolar aspirate specimens. In the study, the virus RNK was detected in 6 of 41 blood samples with a clinical signs of infection. A senior Chinese expert told to the media that the median incubation period is 7 days, ranging from 2-12. The International Health Regulations Emergency Committee for epidemics gives a preliminary estimate for R0 of 1.4-2.5. COVID 19 is mainly transmitted by close contact with the infected by drops due to sneezing and coughing. In a first report of clinical features of infection, the most of patients were presented with fever, cough, myalgia or fatigue. The clinical picture is non-specific. It comes up suddenly exacerbation, bilateral pulmonary which requires admission to intensive care. Initial lethality in hospitalized cases was 15%, but these estimates had to be taken with reserve as the situation evolved. According to recent data, the global fatality rate is 3.7, the lethality rate in China is 3.9% and in Italy 6.8%. According to data from the Chinese Center for Disease Control and Prevention, of 44,672 confirmed cases, 1,023 people died, so letaliett was 2.3%. In the absence of specific prevention and control measures, we are limited to general prevention measures.
References
2. European Centre for Disease Prevention and Control (ECDC). Risk assessment: Outbreak of acute respiratory syndrome associated with a novel coronavirus, Wuhan, China; first update 2020 [updated 22 January 2020]. Available from: https://www.ecdc.europa.eu/en/publications-data/risk-assessment-outbreak-acuterespiratory-syndrome-associated-novel-coronavirus.
3. European Centre for Disease Prevention and Control (ECDC). Facts about severe acute respiratory syndrome (SARS) Stockholm2018 [14 January 2020]. Available from: https://www.ecdc.europa.eu/en/severeacute-respiratory-syndrome/facts.
4. Hui DS, Azhar EI, Kim Y-J, Memish ZA, Oh M-d, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. The Lancet Infectious Diseases. 2018;18(8):e217-e27.
5. WHO. WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China Geneva2020 [updated 9 January 202014 January 2020]. Available from: https://www.who.int/china/news/detail/09-01-2020-whostatement-regarding-cluster-of-pneumonia-cases-in-wuhan-china.
6. Letko M, Munster V. Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV. bioRxiv. 2020:2020.01.22.915660.
7. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine. 2020.
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020.
9. Read JM, Bridgen JRR, Cummings DAT, Ho A, Jewell CP. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. medRxiv. 2020.
10. Ghinai I, McPherson DT, Jennifer C Hunter JC et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. www. The Lancet. Published online March 12, 2020. Available: https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30607-3.pdf
11. D Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly CA, Riley S, et al. Report 3: Transmissibility of 2019-nCoV 2020 [updated 24 January 2020]. Available from: https://www.imperial.ac.uk/mrc-global-infectious-diseaseanalysis/news--wuhan-coronavirus/.
12. Imai N, Dorigatti I, Cori A, Riley S, Ferguson N. Estimating the potential total number of novel Coronavirus (2019-nCoV) cases in Wuhan City, China 2020 [17 January 2020]. Available from: https://www.imperial.ac.uk/mrcglobal-infectious-disease-analysis/news--wuhan-coronavirus/.ecember 2019, indicating that historical sustained transmission in the human population is unlikely
13. Wu P, Hao X, Lau EHY, Wong JY, Leung KSM, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Eurosurveillance. 2020;25(3):2000044.
14. Chinese Center for Disease Control and Prevention Weekly /Vol 2/Nox cited February 11, 2020; https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
15.Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;S2213-2600(20)30079-5; Epub ahead of print. DOIExternal LinkPubMedExternal Link
16.Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, et al. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. J Clin Med. 2020;9:538. DOIExternal LinkPubMedExternal Link
17. Nick Wilson , Amanda Kvalsvig, Lucy Telfar Barnard, and Michael G. Baker Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality. Emerging Infectious Diseases Volume 26, Number 6—June 2020
18. K. Mizumoto and G. Chowell, unpub. data; https://www.medrxiv.org/content/10.1101/2020.02.19.20025163v1External Link).
19. Qun Li, M.Med., Xuhua Guan, Peng Wu, Xiaoye Wang, M.P.H., Lei Zhou, M.Med., Yeqing Tong, Ruiqi Ren, M.Med., Kathy S.M. Leung., Eric H.Y. Lau., Jessica Y. Wong., Xuesen Xing., Nijuan Xiang, M.Med., et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia Јanuary 29, 2020. NEW ENGLAND JOURNAL of MEDICINE, DOI: 10.1056.
20. Min Wei, Jingping Yuan, Yu Liu, Tao Fu, Xue Yu, MS Zhi-Jiang Zhang. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China JAMA Published online February 14, 2020.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).